An ALLG/TROG Prospective Multicentre Study of Involved-Field Radiotherapy with Transplantation for Patients with Hodgkin’s Disease and non-Hodgkin’s Lymphoma

Treatment options for patients with relapsed lymphoma include standard-dose chemotherapy, radiotherapy or high-dose chemotherapy and peripheral blood stem cell transplantation. It has been found that if lymphoma recurs after transplantation it often does so in sites involved prior to transplantation. Radiotherapy can prevent some of these relapses, and may improve the overall results of transplantation. Radiotherapy is often given only to bulky sites (i.e. more than 5-10 cm in size) of lymphoma following transplantation, but the optimal dose and area of radiotherapy is not known. It is possible that treating all the areas of lymphoma (including non-bulky areas) may be more effective. In this research study, radiotherapy was given to all the areas known to be affected by lymphoma (other than bone marrow) with the aims of assessing the ability of radiotherapy to reduce the risk of relapse following transplantation, and carefully evaluating the side effects of adding radiotherapy to transplantation.

Primary Sponsor

Australasian Leukaemia & Lymphoma Group (ALLG)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Participating Centres

Final Accrual


Current Accrual

Trial Chairperson

A/Prof Andrew Wirth
Peter MacCallum Cancer Centre

Related Post

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a

June 15, 2021

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

Ductal carcinoma in situ (DCIS) of the breast is

Skip to toolbar